CTLA4-Ig PLUS BONE MARROW INDUCES LONG-TERM ALLOGRAFT SURVIVAL AND DONOR-SPECIFIC UNRESPONSIVENESS IN THE MURINE MODEL
Thomas C. Pearson(Emory Healthcare), Christian P. Larsen(Emory University Hospital), Eric T. Elwood(Emory University), Kevin J. Winn(Emory University), Diane Z. Alexander(Emory University), Peter S. Linsley(Rosetta Stone (United States)), Rose Hendrix(Emory Healthcare)
Cited by 120
Related Papers
CTLA-4 is a second receptor for the B cell activation antigen B7.
|The Journal of Experimental Medicine|1991|1.7k
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
|Nature|1996|1.5k
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
|The Journal of Experimental Medicine|1997|802
Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing
|RNA|2006|785
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714